Cargando…

Identification of factors associated with the efficacy of atomoxetine in adult attention‐deficit/hyperactivity disorder

AIM: Atomoxetine (ATX) is a non‐central stimulant and a standard treatment for adult attention‐deficit/hyperactivity disorder (ADHD). The long‐term efficacy of Atomoxetine is about 40% at 6 months. The variability in efficacy between individuals is thought to be related to patient‐specific factors,...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagai, Tsutomu, Kurihara, Tatsuya, Koya, Hiroaki, Nakano, Yukako, Sugisawa, Satoru, Sambe, Takehiko, Kishimoto, Keiko, Kogo, Mari, Ota, Haruhisa, Iwanami, Akira, Uchida, Naoki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515700/
https://www.ncbi.nlm.nih.gov/pubmed/35485452
http://dx.doi.org/10.1002/npr2.12253
_version_ 1784798543751413760
author Nagai, Tsutomu
Kurihara, Tatsuya
Koya, Hiroaki
Nakano, Yukako
Sugisawa, Satoru
Sambe, Takehiko
Kishimoto, Keiko
Kogo, Mari
Ota, Haruhisa
Iwanami, Akira
Uchida, Naoki
author_facet Nagai, Tsutomu
Kurihara, Tatsuya
Koya, Hiroaki
Nakano, Yukako
Sugisawa, Satoru
Sambe, Takehiko
Kishimoto, Keiko
Kogo, Mari
Ota, Haruhisa
Iwanami, Akira
Uchida, Naoki
author_sort Nagai, Tsutomu
collection PubMed
description AIM: Atomoxetine (ATX) is a non‐central stimulant and a standard treatment for adult attention‐deficit/hyperactivity disorder (ADHD). The long‐term efficacy of Atomoxetine is about 40% at 6 months. The variability in efficacy between individuals is thought to be related to patient‐specific factors, but no detailed research has been conducted. In this retrospective cohort study, we aimed to identify the factors associated with Atomoxetine efficacy. METHODS: A total of 147 patients with attention‐deficit/hyperactivity disorder aged ≥18 years who were using Atomoxetine for the first time were included in this study. The outcome was treatment success (treatment maintained for at least 6 months and improvement in symptoms). Symptom assessment was based on the overall improvement in symptoms judged by an expert physician. RESULTS: Of the patient sample, 103 (70.1%) achieved the outcome. Logistic regression analysis identified “the maximum dose of ATX” and “gambling habit” as factors associated with efficacy ( P  < 0.05). In the process of Atomoxetine titration, the larger the maximum dose, the higher the efficacy was shown to be. Gambling habits may be indicative of impulsivity, which is among the core symptoms of attention‐deficit/hyperactivity disorder. Thus, a gambling habit may be considered a surrogate marker for impulsivity. CONCLUSIONS: Knowledge of these factors will help healthcare professionals to predict the likely efficacy of Atomoxetine in a given patient before subscribing it, facilitating individualized pharmacotherapy for adult attention‐deficit/hyperactivity disorder.
format Online
Article
Text
id pubmed-9515700
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-95157002022-10-05 Identification of factors associated with the efficacy of atomoxetine in adult attention‐deficit/hyperactivity disorder Nagai, Tsutomu Kurihara, Tatsuya Koya, Hiroaki Nakano, Yukako Sugisawa, Satoru Sambe, Takehiko Kishimoto, Keiko Kogo, Mari Ota, Haruhisa Iwanami, Akira Uchida, Naoki Neuropsychopharmacol Rep Original Articles AIM: Atomoxetine (ATX) is a non‐central stimulant and a standard treatment for adult attention‐deficit/hyperactivity disorder (ADHD). The long‐term efficacy of Atomoxetine is about 40% at 6 months. The variability in efficacy between individuals is thought to be related to patient‐specific factors, but no detailed research has been conducted. In this retrospective cohort study, we aimed to identify the factors associated with Atomoxetine efficacy. METHODS: A total of 147 patients with attention‐deficit/hyperactivity disorder aged ≥18 years who were using Atomoxetine for the first time were included in this study. The outcome was treatment success (treatment maintained for at least 6 months and improvement in symptoms). Symptom assessment was based on the overall improvement in symptoms judged by an expert physician. RESULTS: Of the patient sample, 103 (70.1%) achieved the outcome. Logistic regression analysis identified “the maximum dose of ATX” and “gambling habit” as factors associated with efficacy ( P  < 0.05). In the process of Atomoxetine titration, the larger the maximum dose, the higher the efficacy was shown to be. Gambling habits may be indicative of impulsivity, which is among the core symptoms of attention‐deficit/hyperactivity disorder. Thus, a gambling habit may be considered a surrogate marker for impulsivity. CONCLUSIONS: Knowledge of these factors will help healthcare professionals to predict the likely efficacy of Atomoxetine in a given patient before subscribing it, facilitating individualized pharmacotherapy for adult attention‐deficit/hyperactivity disorder. John Wiley and Sons Inc. 2022-04-29 /pmc/articles/PMC9515700/ /pubmed/35485452 http://dx.doi.org/10.1002/npr2.12253 Text en © 2022 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Nagai, Tsutomu
Kurihara, Tatsuya
Koya, Hiroaki
Nakano, Yukako
Sugisawa, Satoru
Sambe, Takehiko
Kishimoto, Keiko
Kogo, Mari
Ota, Haruhisa
Iwanami, Akira
Uchida, Naoki
Identification of factors associated with the efficacy of atomoxetine in adult attention‐deficit/hyperactivity disorder
title Identification of factors associated with the efficacy of atomoxetine in adult attention‐deficit/hyperactivity disorder
title_full Identification of factors associated with the efficacy of atomoxetine in adult attention‐deficit/hyperactivity disorder
title_fullStr Identification of factors associated with the efficacy of atomoxetine in adult attention‐deficit/hyperactivity disorder
title_full_unstemmed Identification of factors associated with the efficacy of atomoxetine in adult attention‐deficit/hyperactivity disorder
title_short Identification of factors associated with the efficacy of atomoxetine in adult attention‐deficit/hyperactivity disorder
title_sort identification of factors associated with the efficacy of atomoxetine in adult attention‐deficit/hyperactivity disorder
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515700/
https://www.ncbi.nlm.nih.gov/pubmed/35485452
http://dx.doi.org/10.1002/npr2.12253
work_keys_str_mv AT nagaitsutomu identificationoffactorsassociatedwiththeefficacyofatomoxetineinadultattentiondeficithyperactivitydisorder
AT kuriharatatsuya identificationoffactorsassociatedwiththeefficacyofatomoxetineinadultattentiondeficithyperactivitydisorder
AT koyahiroaki identificationoffactorsassociatedwiththeefficacyofatomoxetineinadultattentiondeficithyperactivitydisorder
AT nakanoyukako identificationoffactorsassociatedwiththeefficacyofatomoxetineinadultattentiondeficithyperactivitydisorder
AT sugisawasatoru identificationoffactorsassociatedwiththeefficacyofatomoxetineinadultattentiondeficithyperactivitydisorder
AT sambetakehiko identificationoffactorsassociatedwiththeefficacyofatomoxetineinadultattentiondeficithyperactivitydisorder
AT kishimotokeiko identificationoffactorsassociatedwiththeefficacyofatomoxetineinadultattentiondeficithyperactivitydisorder
AT kogomari identificationoffactorsassociatedwiththeefficacyofatomoxetineinadultattentiondeficithyperactivitydisorder
AT otaharuhisa identificationoffactorsassociatedwiththeefficacyofatomoxetineinadultattentiondeficithyperactivitydisorder
AT iwanamiakira identificationoffactorsassociatedwiththeefficacyofatomoxetineinadultattentiondeficithyperactivitydisorder
AT uchidanaoki identificationoffactorsassociatedwiththeefficacyofatomoxetineinadultattentiondeficithyperactivitydisorder